https://stock.noler.com/us/stock/strongbridge-biopharma-plc https://stock.noler.com/us/stock/strongbridge-biopharma-plc/accounts-payable-current-and-noncurrent https://stock.noler.com/us/stock/strongbridge-biopharma-plc/accounts-receivable https://stock.noler.com/us/stock/strongbridge-biopharma-plc/accrued-liabilities-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/accrued-professional-fees-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/accrued-royalties-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/strongbridge-biopharma-plc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/strongbridge-biopharma-plc/allowance-for-doubtful-accounts-receivable https://stock.noler.com/us/stock/strongbridge-biopharma-plc/amortization https://stock.noler.com/us/stock/strongbridge-biopharma-plc/amortization-of-financing-costs-and-discounts https://stock.noler.com/us/stock/strongbridge-biopharma-plc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/strongbridge-biopharma-plc/aoci https://stock.noler.com/us/stock/strongbridge-biopharma-plc/asset-impairment-charges https://stock.noler.com/us/stock/strongbridge-biopharma-plc/available-for-sale-debt-accumulated-gross-unrealized-gain-loss-before-tax https://stock.noler.com/us/stock/strongbridge-biopharma-plc/available-for-sale-debt-amortized-cost-basis https://stock.noler.com/us/stock/strongbridge-biopharma-plc/available-for-sale-debt-amortized-cost-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/available-for-sale-debt-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/available-for-sale-debt-gross-unrealized-gain https://stock.noler.com/us/stock/strongbridge-biopharma-plc/available-for-sale-debt-noncurrent https://stock.noler.com/us/stock/strongbridge-biopharma-plc/available-for-sale-debt-securities https://stock.noler.com/us/stock/strongbridge-biopharma-plc/basic-shares https://stock.noler.com/us/stock/strongbridge-biopharma-plc/buybacks-payments-for-repurchase-of-equity https://stock.noler.com/us/stock/strongbridge-biopharma-plc/buybacks-shares-repurchased-value https://stock.noler.com/us/stock/strongbridge-biopharma-plc/capital-expenditures https://stock.noler.com/us/stock/strongbridge-biopharma-plc/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/strongbridge-biopharma-plc/cash-and-equivalents https://stock.noler.com/us/stock/strongbridge-biopharma-plc/cash-and-restricted-cash https://stock.noler.com/us/stock/strongbridge-biopharma-plc/cash-cash-equivalents-and-short-term-investments https://stock.noler.com/us/stock/strongbridge-biopharma-plc/cash-flow-breakdown https://stock.noler.com/us/stock/strongbridge-biopharma-plc/class-of-warrant-or-right-outstanding https://stock.noler.com/us/stock/strongbridge-biopharma-plc/common-stock-dividends-per-share-cash-paid https://stock.noler.com/us/stock/strongbridge-biopharma-plc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/strongbridge-biopharma-plc/common-stock-value https://stock.noler.com/us/stock/strongbridge-biopharma-plc/comprehensive-income https://stock.noler.com/us/stock/strongbridge-biopharma-plc/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/strongbridge-biopharma-plc/contract-with-customer-refund-liability https://stock.noler.com/us/stock/strongbridge-biopharma-plc/cost-of-goods-and-service-excluding-depreciation-depletion-and-amortization https://stock.noler.com/us/stock/strongbridge-biopharma-plc/cost-of-goods-sold https://stock.noler.com/us/stock/strongbridge-biopharma-plc/cost-of-goods-sold-excluding-depreciation-depletion-and-amortization https://stock.noler.com/us/stock/strongbridge-biopharma-plc/costs-and-expenses https://stock.noler.com/us/stock/strongbridge-biopharma-plc/cover-page-shares-outstanding https://stock.noler.com/us/stock/strongbridge-biopharma-plc/current-assets https://stock.noler.com/us/stock/strongbridge-biopharma-plc/current-income-tax-expense-benefit https://stock.noler.com/us/stock/strongbridge-biopharma-plc/current-liabilities https://stock.noler.com/us/stock/strongbridge-biopharma-plc/current-portion-of-long-term-debt https://stock.noler.com/us/stock/strongbridge-biopharma-plc/debt-maturing-in-next-twelve-months https://stock.noler.com/us/stock/strongbridge-biopharma-plc/debt-maturing-in-year-five https://stock.noler.com/us/stock/strongbridge-biopharma-plc/debt-maturing-in-year-four https://stock.noler.com/us/stock/strongbridge-biopharma-plc/debt-maturing-in-year-three https://stock.noler.com/us/stock/strongbridge-biopharma-plc/debt-maturing-in-year-two https://stock.noler.com/us/stock/strongbridge-biopharma-plc/debt-repaid https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-income-tax-liabilities https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-assets-goodwill-and-intangible-assets https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-assets-gross https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-assets-liabilities-net-noncurrent https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-assets-net https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-assets-tax-credit-carryforwards https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-assets-tax-deferred-expense-other https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-liabilities https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-liabilities-derivatives https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-liabilities-goodwill-and-intangible-assets-intangible-assets https://stock.noler.com/us/stock/strongbridge-biopharma-plc/deferred-tax-liabilities-noncurrent https://stock.noler.com/us/stock/strongbridge-biopharma-plc/defined-contribution-plan-cost-recognized https://stock.noler.com/us/stock/strongbridge-biopharma-plc/defined-contribution-plan-employer-matching-contribution-percent https://stock.noler.com/us/stock/strongbridge-biopharma-plc/defined-contribution-plan-employer-matching-contribution-percent-of-match https://stock.noler.com/us/stock/strongbridge-biopharma-plc/depreciation https://stock.noler.com/us/stock/strongbridge-biopharma-plc/diluted-shares https://stock.noler.com/us/stock/strongbridge-biopharma-plc/dividends-per-share https://stock.noler.com/us/stock/strongbridge-biopharma-plc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/strongbridge-biopharma-plc/effective-tax-rate https://stock.noler.com/us/stock/strongbridge-biopharma-plc/employee-related-liabilities-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/eps https://stock.noler.com/us/stock/strongbridge-biopharma-plc/eps-basic https://stock.noler.com/us/stock/strongbridge-biopharma-plc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/strongbridge-biopharma-plc/extinguishment-of-debt-amount https://stock.noler.com/us/stock/strongbridge-biopharma-plc/fair-value-adjustment-of-warrants https://stock.noler.com/us/stock/strongbridge-biopharma-plc/financing-cash-flow https://stock.noler.com/us/stock/strongbridge-biopharma-plc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/strongbridge-biopharma-plc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/strongbridge-biopharma-plc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/strongbridge-biopharma-plc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/strongbridge-biopharma-plc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/strongbridge-biopharma-plc/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/strongbridge-biopharma-plc/finitelived-intangible-assets-acquired https://stock.noler.com/us/stock/strongbridge-biopharma-plc/foreign-currency-exchange-rate-remeasurement https://stock.noler.com/us/stock/strongbridge-biopharma-plc/foreign-currency-transaction-gain-loss-before-tax https://stock.noler.com/us/stock/strongbridge-biopharma-plc/foreign-currency-transaction-loss-before-tax https://stock.noler.com/us/stock/strongbridge-biopharma-plc/form-d-other https://stock.noler.com/us/stock/strongbridge-biopharma-plc/form-d-stocks https://stock.noler.com/us/stock/strongbridge-biopharma-plc/gain-or-loss-on-sale-of-stock-in-subsidiary https://stock.noler.com/us/stock/strongbridge-biopharma-plc/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/strongbridge-biopharma-plc/general-and-administrative-expense https://stock.noler.com/us/stock/strongbridge-biopharma-plc/goodwill https://stock.noler.com/us/stock/strongbridge-biopharma-plc/goodwill-acquired https://stock.noler.com/us/stock/strongbridge-biopharma-plc/goodwill-and-intangible-asset-impairment https://stock.noler.com/us/stock/strongbridge-biopharma-plc/impairment-of-intangible-assets-excluding-goodwill https://stock.noler.com/us/stock/strongbridge-biopharma-plc/impairment-of-intangible-assets-indefinitelived-excluding-goodwill https://stock.noler.com/us/stock/strongbridge-biopharma-plc/income-tax https://stock.noler.com/us/stock/strongbridge-biopharma-plc/income-taxes-paid https://stock.noler.com/us/stock/strongbridge-biopharma-plc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/strongbridge-biopharma-plc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/strongbridge-biopharma-plc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/strongbridge-biopharma-plc/increase-decrease-in-accrued-liabilities-and-other-operating-liabilities https://stock.noler.com/us/stock/strongbridge-biopharma-plc/increase-decrease-in-inventories https://stock.noler.com/us/stock/strongbridge-biopharma-plc/increase-decrease-in-other-noncurrent-assets https://stock.noler.com/us/stock/strongbridge-biopharma-plc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/strongbridge-biopharma-plc/incremental-common-shares-attributable-to-share-based-payment-arrangements https://stock.noler.com/us/stock/strongbridge-biopharma-plc/indefinite-lived-intangible-assets-excluding-goodwill https://stock.noler.com/us/stock/strongbridge-biopharma-plc/insider-transactions-stock-options https://stock.noler.com/us/stock/strongbridge-biopharma-plc/insider-transactions-warrants https://stock.noler.com/us/stock/strongbridge-biopharma-plc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/strongbridge-biopharma-plc/intangible-assets-net-including-goodwill https://stock.noler.com/us/stock/strongbridge-biopharma-plc/interest-expense https://stock.noler.com/us/stock/strongbridge-biopharma-plc/interest-paid https://stock.noler.com/us/stock/strongbridge-biopharma-plc/interest-paid-net https://stock.noler.com/us/stock/strongbridge-biopharma-plc/interest-payable-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/inventory https://stock.noler.com/us/stock/strongbridge-biopharma-plc/investing-cash-flow https://stock.noler.com/us/stock/strongbridge-biopharma-plc/investment-income-amortization-of-discount https://stock.noler.com/us/stock/strongbridge-biopharma-plc/lease-cost https://stock.noler.com/us/stock/strongbridge-biopharma-plc/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/strongbridge-biopharma-plc/liabilities-assumed https://stock.noler.com/us/stock/strongbridge-biopharma-plc/long-term-debt https://stock.noler.com/us/stock/strongbridge-biopharma-plc/maturities-of-available-for-sale-securities https://stock.noler.com/us/stock/strongbridge-biopharma-plc/minority-interest https://stock.noler.com/us/stock/strongbridge-biopharma-plc/minority-interest-decrease-from-redemptions https://stock.noler.com/us/stock/strongbridge-biopharma-plc/net-change-in-cash https://stock.noler.com/us/stock/strongbridge-biopharma-plc/net-income https://stock.noler.com/us/stock/strongbridge-biopharma-plc/net-income-loss-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/strongbridge-biopharma-plc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/strongbridge-biopharma-plc/net-income-loss-available-to-common-stockholders-diluted https://stock.noler.com/us/stock/strongbridge-biopharma-plc/number-of-operating-segments https://stock.noler.com/us/stock/strongbridge-biopharma-plc/number-of-reporting-units https://stock.noler.com/us/stock/strongbridge-biopharma-plc/oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-cash-flow https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-expenses https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-income https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-assets https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-liability https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-liability-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due-2 https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-leases-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/strongbridge-biopharma-plc/operating-leases-rent-expense-net https://stock.noler.com/us/stock/strongbridge-biopharma-plc/other-accrued-liabilities-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/other-income https://stock.noler.com/us/stock/strongbridge-biopharma-plc/other-noncurrent-assets https://stock.noler.com/us/stock/strongbridge-biopharma-plc/other-noncurrent-liabilities https://stock.noler.com/us/stock/strongbridge-biopharma-plc/other-nonoperating-income-expense https://stock.noler.com/us/stock/strongbridge-biopharma-plc/other-than-temporary-impairment-losses-investments-portion-recognized-in-earnings-net https://stock.noler.com/us/stock/strongbridge-biopharma-plc/paid-in-capital-shares-issued-issuance-costs https://stock.noler.com/us/stock/strongbridge-biopharma-plc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/strongbridge-biopharma-plc/paid-in-capital-warrant-issued https://stock.noler.com/us/stock/strongbridge-biopharma-plc/paid-in-kind-interest https://stock.noler.com/us/stock/strongbridge-biopharma-plc/payments-of-debt-extinguishment-costs https://stock.noler.com/us/stock/strongbridge-biopharma-plc/payments-of-debt-issuance-costs https://stock.noler.com/us/stock/strongbridge-biopharma-plc/payments-to-acquire-available-for-sale-debt https://stock.noler.com/us/stock/strongbridge-biopharma-plc/payments-to-acquire-businesses-and-interest-in-affiliates https://stock.noler.com/us/stock/strongbridge-biopharma-plc/payments-to-acquire-investments https://stock.noler.com/us/stock/strongbridge-biopharma-plc/payments-to-acquire-machinery-and-equipment https://stock.noler.com/us/stock/strongbridge-biopharma-plc/payments-to-minority-shareholders https://stock.noler.com/us/stock/strongbridge-biopharma-plc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/pretax-income https://stock.noler.com/us/stock/strongbridge-biopharma-plc/proceeds-from-divestiture-of-businesses-and-interests-in-affiliates https://stock.noler.com/us/stock/strongbridge-biopharma-plc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/strongbridge-biopharma-plc/proceeds-from-issuance-of-debt https://stock.noler.com/us/stock/strongbridge-biopharma-plc/proceeds-from-issuance-or-sale-of-equity https://stock.noler.com/us/stock/strongbridge-biopharma-plc/proceeds-from-sale-and-maturity-of-available-for-sale-securities https://stock.noler.com/us/stock/strongbridge-biopharma-plc/proceeds-from-sale-of-available-for-sale-debt https://stock.noler.com/us/stock/strongbridge-biopharma-plc/proceeds-from-stock-issued https://stock.noler.com/us/stock/strongbridge-biopharma-plc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/strongbridge-biopharma-plc/proceeds-from-warrant-exercises https://stock.noler.com/us/stock/strongbridge-biopharma-plc/profit-loss https://stock.noler.com/us/stock/strongbridge-biopharma-plc/property-plant-equipment https://stock.noler.com/us/stock/strongbridge-biopharma-plc/public-float https://stock.noler.com/us/stock/strongbridge-biopharma-plc/repayments-of-debt https://stock.noler.com/us/stock/strongbridge-biopharma-plc/research-and-development https://stock.noler.com/us/stock/strongbridge-biopharma-plc/retained-earnings https://stock.noler.com/us/stock/strongbridge-biopharma-plc/revenue https://stock.noler.com/us/stock/strongbridge-biopharma-plc/revenue-from-contract-with-customer-excluding-assessed-tax https://stock.noler.com/us/stock/strongbridge-biopharma-plc/revenue-recognition-sales-returns-reserve-for-sales-returns https://stock.noler.com/us/stock/strongbridge-biopharma-plc/sales-revenue-net https://stock.noler.com/us/stock/strongbridge-biopharma-plc/sga-expense https://stock.noler.com/us/stock/strongbridge-biopharma-plc/shares-authorized https://stock.noler.com/us/stock/strongbridge-biopharma-plc/shares-issued https://stock.noler.com/us/stock/strongbridge-biopharma-plc/shares-issued-price-per-share https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-award-fair-value-assumptions-expected-volatility-rate-maximum https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-award-fair-value-assumptions-expected-volatility-rate-minimum https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-award-fair-value-assumptions-risk-free-interest-rate-maximum https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-award-fair-value-assumptions-risk-free-interest-rate-minimum https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-award-options-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-based-compensation https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-compensation-tax-benefit-from-compensation-expense https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-issued-shares-issued-value-stock-options-exercised-net-of-tax-benefit-expense https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-issued-value-of-shares-issued-for-stock-awards https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-exercisable-number https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-expirations-in-period https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-forfeitures-and-expirations-in-period https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-forfeitures-and-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-outstanding-number https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-options-vested-in-period-fair-value https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stock-split-ratio https://stock.noler.com/us/stock/strongbridge-biopharma-plc/stockholders-equity-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/strongbridge-biopharma-plc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/strongbridge-biopharma-plc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/strongbridge-biopharma-plc/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/strongbridge-biopharma-plc/tax-rate-reconciliation-disposition-of-business https://stock.noler.com/us/stock/strongbridge-biopharma-plc/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/strongbridge-biopharma-plc/tax-rate-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/strongbridge-biopharma-plc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/strongbridge-biopharma-plc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/strongbridge-biopharma-plc/tax-rate-reconciliation-tax-credits https://stock.noler.com/us/stock/strongbridge-biopharma-plc/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/strongbridge-biopharma-plc/tax-withholding-on-stock-awards https://stock.noler.com/us/stock/strongbridge-biopharma-plc/taxes-payable-current https://stock.noler.com/us/stock/strongbridge-biopharma-plc/total-assets https://stock.noler.com/us/stock/strongbridge-biopharma-plc/total-liabilities https://stock.noler.com/us/stock/strongbridge-biopharma-plc/total-liabilities-and-equity https://stock.noler.com/us/stock/strongbridge-biopharma-plc/total-long-term-debt https://stock.noler.com/us/stock/strongbridge-biopharma-plc/utb-income-tax-penalties-and-interest-accrued https://stock.noler.com/us/stock/strongbridge-biopharma-plc/utb-income-tax-penalties-and-interest-expense https://stock.noler.com/us/stock/strongbridge-biopharma-plc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/strongbridge-biopharma-plc/warrants-and-rights-outstanding https://stock.noler.com/us/stock/strongbridge-biopharma-plc/weighted-average-number-of-share-outstanding-basic-and-diluted https://stock.noler.com/us/stock/strongbridge-biopharma-plc/write-off-of-deferred-debt-issuance-cost